Partnership expands BC Platforms' global patient catchment to include an additional 48 million patient lives across Asia, the Middle East,...
Partnership Brings AI-Powered Denial Prevention and Appeals Automation to 250-Provider GroupNEW YORK, Dec. 17, 2025 /PRNewswire/ -- Protego Health, a leading...
TORONTO, Dec. 17, 2025 /PRNewswire/ -- Xtalks — The Life Science Community™, a leading B2B digital media platform serving the...
MIAMI, FL / ACCESS Newswire / December 17, 2025 / KIFFIK Biomedical announced today the successful close of its Series...
Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17,...
Collaborations with Cercare Medical and Circle CVI bring advanced AI for MR Perfusion and automated ASPECTS scoring to Aidoc's aiOS™...
Collaborations with Cercare Medical and Circle CVI bring advanced AI for MR Perfusion and automated ASPECTS scoring to Aidoc's aiOS™...
Company Enters 2026 Positioned for Wide-Scale Deployment, Fueled by $50M Series A, 40+ Global Sponsors, and Measurable ROIBOSTON, Dec. 16,...
Company Enters 2026 Positioned for Wide-Scale Deployment, Fueled by $50M Series A, 40+ Global Sponsors, and Measurable ROIBOSTON, Dec. 16,...
KENNEWICK, Wash. and HOUSTON, Dec. 11, 2025 /PRNewswire/ -- Cadwell, a global leader in neurodiagnostic and monitoring solutions, and Medical...
Publication in key market advances NewcelX's global IP strategy across Asia and supports the Company's expanding position in neurology and...
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease Results show, for...
LAVAL, QC / ACCESS Newswire / December 8, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") announced today the...
NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Imre today announced the appointment of Nadine Lafond as its new Chief Executive...
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in NovemberAgreement includes...
Phase 2 results selected as one of only 10 featured presentations in the Poster Tour at the 2025 Parkinson Study...
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)...
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1...
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire...
First video-documented ALS reversal marks a new era for brain health achieved through noninvasive computerized brain-temperature modulation, confirmed by electrophysiological,...